While systemic therapy for non-metastatic, invasive breast cancer is provided to minimize the risk of recurrence, neoadjuvant therapy (NAT) is given prior to surgery to downstage the tumor and to evaluate treatment response. Downstaging the tumor may allow for less invasive surgery on the breast and axilla, thus avoiding the need for breast reconstruction, improving cosmetic outcomes, and reducing postoperative complications. With the rising number of NAT candidates, it is becoming increasingly important to standardize how tumor response is assessed after surgery. In the post-NAT setting, macroscopic assessment of surgical samples, extent of sampling for histology, and microscopic analysis require a different approach than in the primary surgery setting. In the neo-adjuvant setting, the close collaboration of pathologists, oncologists, surgeons, and radiologists within the multidisciplinary team is essential to ensure the best possible management of breast cancer patients. Here, we provide an update on the suggested procedures for an accurate assessment of tumor response to NAT, including the evaluation of all relevant parameters that correlate with long-term prognosis and inform the subsequent adjuvant interventions.

Pathology after neoadjuvant treatment – How to assess residual disease / G. Viale, N. Fusco. - In: THE BREAST. - ISSN 0960-9776. - 62:Supp. 1(2022 Apr 25), pp. 25-28. [10.1016/j.breast.2021.11.009]

Pathology after neoadjuvant treatment – How to assess residual disease

G. Viale
Primo
;
N. Fusco
Ultimo
2022-04-25

Abstract

While systemic therapy for non-metastatic, invasive breast cancer is provided to minimize the risk of recurrence, neoadjuvant therapy (NAT) is given prior to surgery to downstage the tumor and to evaluate treatment response. Downstaging the tumor may allow for less invasive surgery on the breast and axilla, thus avoiding the need for breast reconstruction, improving cosmetic outcomes, and reducing postoperative complications. With the rising number of NAT candidates, it is becoming increasingly important to standardize how tumor response is assessed after surgery. In the post-NAT setting, macroscopic assessment of surgical samples, extent of sampling for histology, and microscopic analysis require a different approach than in the primary surgery setting. In the neo-adjuvant setting, the close collaboration of pathologists, oncologists, surgeons, and radiologists within the multidisciplinary team is essential to ensure the best possible management of breast cancer patients. Here, we provide an update on the suggested procedures for an accurate assessment of tumor response to NAT, including the evaluation of all relevant parameters that correlate with long-term prognosis and inform the subsequent adjuvant interventions.
Biomarkers; Breast cancer; Neoadjuvant therapy; Pathologic complete response
Settore MED/08 - Anatomia Patologica
16-nov-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
[2021] [Breast] Pathology-after-neoadjuvant-treatme.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 240.28 kB
Formato Adobe PDF
240.28 kB Adobe PDF Visualizza/Apri
1-s2.0-S0960977621009905-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 271.56 kB
Formato Adobe PDF
271.56 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/891720
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 0
social impact